The Life Sciences team advised PepGen, Inc. on its initial public offering of 9,000,000 shares of common stock at an initial public offering price of $12.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses payable by PepGen, are expected to be $108.0 million. In addition, PepGen has granted the underwriters a 30-day option to purchase up to an additional 1,350,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions.
PepGen is a clinical-stage biotechnology company advancing the next-generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases.
The Goodwin team was led by Richard Hoffman and Alicia Tschirhart, and included Amanda Rae Schwarzenbart, Sebastian Miao (Corporate and Securities); Julie Tibbets and Crescent Moran Chasteen, James Devendorf, Roger Cohen and Heath Ingram (Healthcare Regulatory).
For more details, read the press release and articles in Endpoints and Fierce Biotech.